Jubilant Pharma Singapore Announces Sale of 25.8% Stake in Sofie Biosciences and Subsequent Merger, with Potential $139.4 Million Proceeds

Jubilant Pharma Singapore is set to sell its entire 25.8% stake in Sofie Biosciences, with the anticipated proceeds reaching up to $139.4 million.

Sofie Biosciences is scheduled to merge with Trilantic North America by June 30.

If the merger transaction falls through, Jubilant Pharma Singapore is poised to receive termination-related fees of up to $7 million from Sofie.